SG157244A1 - Point of care test for the detection of exposure or immunity to dengue virus - Google Patents

Point of care test for the detection of exposure or immunity to dengue virus

Info

Publication number
SG157244A1
SG157244A1 SG200803904-2A SG2008039042A SG157244A1 SG 157244 A1 SG157244 A1 SG 157244A1 SG 2008039042 A SG2008039042 A SG 2008039042A SG 157244 A1 SG157244 A1 SG 157244A1
Authority
SG
Singapore
Prior art keywords
dengue virus
binding partner
exposure
detection
point
Prior art date
Application number
SG200803904-2A
Inventor
Bijon Kumar Sil
Tan Yun Ying
Original Assignee
Mp Biomedicals Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mp Biomedicals Asia Pacific Pte Ltd filed Critical Mp Biomedicals Asia Pacific Pte Ltd
Priority to SG200803904-2A priority Critical patent/SG157244A1/en
Priority to MX2010012363A priority patent/MX2010012363A/en
Priority to PCT/SG2009/000138 priority patent/WO2009139725A1/en
Priority to BRPI0915291A priority patent/BRPI0915291A2/en
Publication of SG157244A1 publication Critical patent/SG157244A1/en
Priority to CO10148450A priority patent/CO6311040A2/en
Priority to CR11836A priority patent/CR11836A/en
Priority to EC2010010680A priority patent/ECSP10010680A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides a "point of care test" (POCT) for detecting a subject who has had exposure to a dengue virus or immunological relative thereof or who has achieved some level of immunity against a dengue virus antigen. The method is predicted in part on the detection of a binding partner which is specific for a dengue virus or an immunological relative thereof. The POCT comprises contacting a biological sample from the subject with a mixture of dengue virus specific immunogenic components; and determining the presence of a complex that forms between a binding partner in the biological sample and a dengue virus specific immunogenic component; and characterizing the binding partner in the complex with an anti-binding partner antibody conjugated with gold colloid using reverse flow technology.
SG200803904-2A 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus SG157244A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SG200803904-2A SG157244A1 (en) 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus
MX2010012363A MX2010012363A (en) 2008-05-15 2009-04-15 Point of care test for the detection of exposure or immunity to dengue virus.
PCT/SG2009/000138 WO2009139725A1 (en) 2008-05-15 2009-04-15 Point of care test for the detection of exposure or immunity to dengue virus
BRPI0915291A BRPI0915291A2 (en) 2008-05-15 2009-04-15 point of care test for detection of dengue virus exposure or immunity
CO10148450A CO6311040A2 (en) 2008-05-15 2010-11-25 CARE TEST POINT FOR DETECTION OF A SUBJECT EXPOSED TO THE DENGUE VIRUS OR THAT HAS REACHED A CERTAIN LEVEL OF IMMUNITY AGAINST AN ANTIGEN OF THE DENGUE VIRUS
CR11836A CR11836A (en) 2008-05-15 2010-12-09 IMMEDIATE DIAGNOSTIC TEST FOR DETECTION OF EXPOSURE OR IMMUNITY AGAINST DENGUE VIRUS
EC2010010680A ECSP10010680A (en) 2008-05-15 2010-12-15 TEST OF THE CARE POINT FOR THE DETECTION OF EXPOSURE OR IMMUNITY TO THE DENGUE VIRUS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200803904-2A SG157244A1 (en) 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus

Publications (1)

Publication Number Publication Date
SG157244A1 true SG157244A1 (en) 2009-12-29

Family

ID=41318932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200803904-2A SG157244A1 (en) 2008-05-15 2008-05-15 Point of care test for the detection of exposure or immunity to dengue virus

Country Status (7)

Country Link
BR (1) BRPI0915291A2 (en)
CO (1) CO6311040A2 (en)
CR (1) CR11836A (en)
EC (1) ECSP10010680A (en)
MX (1) MX2010012363A (en)
SG (1) SG157244A1 (en)
WO (1) WO2009139725A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG165194A1 (en) * 2009-03-20 2010-10-28 Mp Biomedicals Asia Pacific Pte Ltd Point of care test for the detection of exposure to hev immunoglobulin a (iga)
CN102393454A (en) * 2011-08-24 2012-03-28 中国检验检疫科学研究院 Colloidal gold test strip for detecting dengue virus antibody and preparation method and application thereof
PL3539565T3 (en) 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
SG10201404571PA (en) * 2014-08-01 2016-03-30 Mp Biomedicals Asia Pacific Pte Ltd Method and kit for detecting a dengue virus infection
MX2021002586A (en) 2018-09-05 2021-06-08 Takeda Vaccines Inc Dengue vaccine unit dose and administration thereof.
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
WO2021202992A2 (en) * 2020-04-03 2021-10-07 Lawrence Loomis Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
EP4138913A1 (en) * 2020-04-24 2023-03-01 Massachusetts Institute of Technology Rapid, point of care detection of neutralizing antibodies against a virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03148066A (en) * 1989-11-06 1991-06-24 Nippon Zeon Co Ltd Membrane for diagnosing virus infectious disease and diagnostic method
KR20010022452A (en) * 1997-07-31 2001-03-15 추후제출 Recombinant dimeric envelope vaccine against flaviviral infection
FR2767324B1 (en) * 1997-08-14 2001-04-06 Pasteur Institut USE OF RECOMBINANT ENVELOPE PROTEINS FOR THE DIAGNOSIS OF DENGUE VIRUS
WO2005014627A1 (en) * 2003-08-07 2005-02-17 International Centre For Genetic Engineering And Biotechnology Recombinant dengue multi epitope proteins as diagnostic intermediates
SG137711A1 (en) * 2006-05-11 2007-12-28 Nat Environment Agency Antigen capture anti-dengue iga elisa (aca-elisa) for the detection of a flavivirus specific antibody

Also Published As

Publication number Publication date
CR11836A (en) 2011-06-07
WO2009139725A1 (en) 2009-11-19
MX2010012363A (en) 2011-04-11
ECSP10010680A (en) 2011-04-29
CO6311040A2 (en) 2011-08-22
BRPI0915291A2 (en) 2016-02-16

Similar Documents

Publication Publication Date Title
SG157244A1 (en) Point of care test for the detection of exposure or immunity to dengue virus
SG135990A1 (en) Competitive enzyme linked immunosorbent assay (c-elisa) for the detection of a flavivirus specific antibody
MX2009004460A (en) Immunoassay of analytes in samples containing endogenous anti-analyte antibodies.
ATE445163T1 (en) METHOD FOR ASSESSING THE RISK AND PRESIDENCY OF DEVELOPING SYMPTOMS ASSOCIATED WITH THE PRESENCE OF ANTI-EPCR ANTIBODIES
TR201818881T4 (en) Signal Amplification Immunoassays
BR112017002209A2 (en) method and kit for detecting a dengue virus infection
TW200740840A (en) Diagnostic test kits
MX2010013692A (en) Detection of cannabis use.
TW200741203A (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
WO2010011357A3 (en) Detection of prostate cancer using psa glycosylation patterns
DE602005009819D1 (en) METHOD FOR DETECTING INFECTIONS WITH MYCOBACTERIES
EA200700345A1 (en) ENRICHED ANTIBODY FOR THE IDENTIFICATION OF MYCOBACTERIAL INFECTION, METHODS OF APPLICATION AND DIAGNOSTIC TESTS USING SUCH ANTIBODY
BR0200986A (en) Hepatitis C Antigen - Antibody Combination Assay for Early Detection of Infection
SG165194A1 (en) Point of care test for the detection of exposure to hev immunoglobulin a (iga)
WO2008067008A3 (en) A method for the quantitative evaluation of sex hormones in a serum sample
ATE496300T1 (en) IMMUNE TEST METHOD AND CHIP
DE602005022199D1 (en) ADJUSTMENT OF IMMUNE RESPONSES
GB2455929A (en) A method for the identification of human immunodeficiency virus related antibodies in blood
GB2454852A (en) A method for screening of infectious agents in blood
WO2008067003A3 (en) A method to detect virus related immunological markers for the diagnosis of respiratory tract infections
RU2012127077A (en) METHOD OF IMMUNOCHROMATOGRAPHIC ANALYSIS FOR SERODIAGNOSTICS
WO2010053772A3 (en) Disease-associated antigens and methods of use thereof
ATE520985T1 (en) METHOD FOR DETERMINING ANTIGEN AND ANTIBODIES AGAINST THE ANTIGEN
RU2007140911A (en) METHOD FOR IDENTIFICATION OF ANTIGENS AND ANTIBODIES IN AN IMMUNO-ENZYMAL ANALYSIS
WO2004019038A3 (en) Method for the detection of antibodies and/or antigens in a test liquid, particularly for determining the blood type